BioSyent Résultats passés
Passé contrôle des critères 5/6
BioSyent has been growing earnings at an average annual rate of 9.3%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 9.1% per year. BioSyent's return on equity is 20.2%, and it has net margins of 21.1%.
Informations clés
9.3%
Taux de croissance des bénéfices
13.0%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 23.1% |
Taux de croissance des recettes | 9.1% |
Rendement des fonds propres | 20.2% |
Marge nette | 21.1% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
BioSyent's (CVE:RX) Dividend Will Be CA$0.045
Aug 30BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Ventilation des recettes et des dépenses
Comment BioSyent gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 34 | 7 | 19 | 0 |
31 Mar 24 | 33 | 7 | 18 | 0 |
31 Dec 23 | 32 | 6 | 18 | 0 |
30 Sep 23 | 31 | 6 | 18 | 0 |
30 Jun 23 | 29 | 5 | 17 | 0 |
31 Mar 23 | 27 | 5 | 16 | 0 |
31 Dec 22 | 28 | 5 | 16 | 0 |
30 Sep 22 | 28 | 6 | 15 | 0 |
30 Jun 22 | 28 | 6 | 14 | 0 |
31 Mar 22 | 28 | 6 | 14 | 0 |
31 Dec 21 | 29 | 6 | 14 | 0 |
30 Sep 21 | 27 | 5 | 14 | 0 |
30 Jun 21 | 26 | 4 | 15 | 0 |
31 Mar 21 | 24 | 4 | 13 | 0 |
31 Dec 20 | 22 | 4 | 12 | 0 |
30 Sep 20 | 22 | 4 | 11 | 0 |
30 Jun 20 | 23 | 5 | 11 | 0 |
31 Mar 20 | 23 | 5 | 11 | 0 |
31 Dec 19 | 21 | 4 | 10 | 0 |
30 Sep 19 | 22 | 5 | 10 | 0 |
30 Jun 19 | 21 | 5 | 10 | 0 |
31 Mar 19 | 22 | 6 | 10 | 0 |
31 Dec 18 | 22 | 6 | 10 | 0 |
30 Sep 18 | 22 | 5 | 10 | 0 |
30 Jun 18 | 22 | 6 | 10 | 0 |
31 Mar 18 | 21 | 5 | 10 | 0 |
31 Dec 17 | 21 | 5 | 10 | 0 |
30 Sep 17 | 20 | 5 | 9 | 0 |
30 Jun 17 | 19 | 5 | 9 | 0 |
31 Mar 17 | 18 | 4 | 8 | 0 |
31 Dec 16 | 18 | 4 | 8 | 0 |
30 Sep 16 | 17 | 4 | 8 | 0 |
30 Jun 16 | 17 | 4 | 8 | 0 |
31 Mar 16 | 16 | 4 | 8 | 0 |
31 Dec 15 | 15 | 4 | 7 | 0 |
30 Sep 15 | 15 | 4 | 6 | 0 |
30 Jun 15 | 14 | 4 | 6 | 0 |
31 Mar 15 | 13 | 4 | 5 | 0 |
31 Dec 14 | 12 | 3 | 5 | 0 |
30 Sep 14 | 11 | 3 | 5 | 0 |
30 Jun 14 | 10 | 3 | 5 | 0 |
31 Mar 14 | 9 | 2 | 4 | 0 |
31 Dec 13 | 8 | 2 | 4 | 0 |
Des revenus de qualité: RX has a high level of non-cash earnings.
Augmentation de la marge bénéficiaire: RX's current net profit margins (21.1%) are higher than last year (18.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: RX's earnings have grown by 9.3% per year over the past 5 years.
Accélération de la croissance: RX's earnings growth over the past year (34.6%) exceeds its 5-year average (9.3% per year).
Bénéfices par rapport au secteur d'activité: RX earnings growth over the past year (34.6%) exceeded the Pharmaceuticals industry -40.8%.
Rendement des fonds propres
ROE élevé: RX's Return on Equity (20.2%) is considered high.